Dynavax Technologies Corporation (DVAX) Shares are Down -4.66%

Dynavax Technologies Corporation (DVAX) has risen sharply, recording gains of 5.42% in the past 4 weeks. However, the stock has corrected -4.66% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.34% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.29% and the 50-Day Moving Average is 5.28%. Dynavax Technologies Corporation (NASDAQ:DVAX): On Fridays trading session , Opening price of the stock was $16.09 with an intraday high of $16.15. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $15.8. However, the stock managed to close at $15.95, a loss of 0.68% for the day. On the previous day, the stock had closed at $16.06. The total traded volume of the day was 507,484 shares.


The company Insiders own 2% of Dynavax Technologies Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 31.59% . Institutional Investors own 86.51% of Dynavax Technologies Corporation shares. During last six month period, the net percent change held by insiders has seen a change of 110%.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.